BR102012027409B1 - composição farmacêutica e seu método de preparo - Google Patents

composição farmacêutica e seu método de preparo Download PDF

Info

Publication number
BR102012027409B1
BR102012027409B1 BR102012027409-4A BR102012027409A BR102012027409B1 BR 102012027409 B1 BR102012027409 B1 BR 102012027409B1 BR 102012027409 A BR102012027409 A BR 102012027409A BR 102012027409 B1 BR102012027409 B1 BR 102012027409B1
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
group
surfactant
organic solvent
composition according
Prior art date
Application number
BR102012027409-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR102012027409A2 (pt
Inventor
Kim Dong-Yeon
Shin Jae Soo
Lim Hyun Tae
Kim Dae Sung
Lee Seung Hyoun
Sung Jun Ho
Original Assignee
Il-Yang Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il-Yang Pharm. Co., Ltd. filed Critical Il-Yang Pharm. Co., Ltd.
Publication of BR102012027409A2 publication Critical patent/BR102012027409A2/pt
Publication of BR102012027409B1 publication Critical patent/BR102012027409B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR102012027409-4A 2012-03-27 2012-10-25 composição farmacêutica e seu método de preparo BR102012027409B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120031154A KR101956586B1 (ko) 2012-03-27 2012-03-27 약제학적 조성물 및 이의 제조방법
KR10-2012-0031154 2012-03-27

Publications (2)

Publication Number Publication Date
BR102012027409A2 BR102012027409A2 (pt) 2016-07-05
BR102012027409B1 true BR102012027409B1 (pt) 2021-06-22

Family

ID=49260622

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102012027409-4A BR102012027409B1 (pt) 2012-03-27 2012-10-25 composição farmacêutica e seu método de preparo

Country Status (9)

Country Link
KR (1) KR101956586B1 (zh)
AR (1) AR086951A1 (zh)
BR (1) BR102012027409B1 (zh)
IL (1) IL234614B (zh)
SA (1) SA112330839B1 (zh)
TW (1) TWI597063B (zh)
UA (1) UA110882C2 (zh)
WO (1) WO2013147414A1 (zh)
ZA (1) ZA201203616B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1806129A1 (en) * 2004-10-01 2007-07-11 Eisai R&D Management Co., Ltd. Composition containing fine particles and process for producing the same
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
KR20100021321A (ko) * 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263

Also Published As

Publication number Publication date
BR102012027409A2 (pt) 2016-07-05
ZA201203616B (en) 2013-01-30
KR101956586B1 (ko) 2019-03-11
TW201338780A (zh) 2013-10-01
UA110882C2 (uk) 2016-02-25
SA112330839B1 (ar) 2015-08-19
WO2013147414A1 (en) 2013-10-03
KR20130109425A (ko) 2013-10-08
TWI597063B (zh) 2017-09-01
AR086951A1 (es) 2014-02-05
IL234614B (en) 2018-02-28

Similar Documents

Publication Publication Date Title
JP6932746B2 (ja) エンザルタミドの製剤
US10034854B2 (en) Pharmaceutical composition with improved bioavailability
ES2561618T3 (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
BR112012003592B1 (pt) composição farmacêutica contendo derivado de quinolina
ES2654207T3 (es) Composición farmacéutica que contiene fimarsatán e hidroclorotiazida
ES2471076T3 (es) Compuestos de inclusión de silodoxina-ciclodextrina
JP7428356B2 (ja) 高いバイオアベイラビリティを有するソラフェニブの医薬組成物、ソラフェニブ経口固形製剤、及びその使用
BR112021015825B1 (pt) Formulação de afabicina e método para obtenção da mesma
CN109963565B (zh) 一种药物组合物及其制备方法
BR102012027409B1 (pt) composição farmacêutica e seu método de preparo
KR20140146096A (ko) 캡슐 제형
US20170143678A1 (en) Pharmaceutical composition for oral administration
Giri et al. Carriers used for the development of solid dispersion for poorly watersoluble drugs
JP4603803B2 (ja) 放出制御医薬組成物およびこれを用いる製剤
BR112020014306B1 (pt) Composição farmacêutica
BRPI0607372B1 (pt) Medicamento destinado à administração oral, compreendendo um inibidor da ciclooxigenase-2, e método de preparação do mesmo

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/10/2012, OBSERVADAS AS CONDICOES LEGAIS.